A Multicenter, Open-Label, Phase I/II Study of EOS884448 (EOS-448) in Combination With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Belrestotug (Primary) ; Dostarlimab (Primary) ; Inupadenant (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TIG-006
- Sponsors iTeos Therapeutics
- 19 Jun 2024 Planned End Date changed from 1 Jan 2025 to 1 Jul 2025.
- 19 Jun 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Jul 2024.
- 19 Jun 2024 Status changed from recruiting to active, no longer recruiting.